JAK2 and myelofibrosis: There was no statistically significant difference in Beclin-1 expression depending on age, sex, origin of myelofibrosis, grade of bone marrow fibrosis, JAK2 mutational status, nor DIPSS disease risk in PMF and Mysec-PM disease risk in SMF patients (p > 0.05 for all comparisons, Table 1).